MedTrace Logo

Topical Application of AS101 for the Treatment of Psoriasis

NCT00788424 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-07-23

No results posted yet for this study

Summary

This protocol relates to a phase II randomized double blind, placebo controlled study of the AS101 topical application for the treatment of mild to moderate Psoriasis.

Conditions

  • Mild to Moderate Psoriasis

Interventions

DRUG

AS101 Cream

4% AS101 Cream or Placebo cream, twice a day for 12 weeks

Sponsors & Collaborators

  • BioMAS Ltd

    lead INDUSTRY

Principal Investigators

  • Arie Ingbar, Prof · Hadassah Medical Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00788424 on ClinicalTrials.gov